Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Niederland, Judith
ARES, NCT04769895 / 2021-001841-11: MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients	Active, not recruiting	3	66	Europe	MaaT013	MaaT Pharma, MaaT Pharma	Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD	11/24	11/25
IDUNN, NCT04629833 / 2019-001462-15: Treatment of Steroid-Refractory Acute Graft-versus-host Disease with Mesenchymal Stromal Cells Versus Best Available Therapy	Recruiting	3	210	Europe	MC0518, BAT	medac GmbH	Steroid-refractory Acute Graft-versus-host Disease	08/27	08/30
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients	Active, not recruiting	2	168	Europe, RoW	MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab	Miltenyi Biomedicine GmbH, ICON plc	Diffuse Large B-cell Lymphoma	12/24	07/29
PHOEBUS, NCT05762211: Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications ( Trial)	Recruiting	2	387	Europe	Pooled allogeneic fecal microbiotherapy, MaaT033, Placebo	MaaT Pharma	Transplant Complication	10/26	02/27